Results 171 to 180 of about 489,862 (290)

Ovarian Matrisome Dynamics and αvβ3‐Mediated Regulation in Early Follicular Development

Advanced Science, EarlyView.
The matrisome undergoes dynamic remodeling during early follicular development. Integrin αvβ3 mediates matrisome signals, regulating primordial follicle activation/atresia and secondary follicle growth via Hippo/mTOR pathways, with conserved roles in human ovaries, offering therapeutic targets for ovarian disorders.
Tong Wu, Yanzhi Feng, Qingqing Zhu, Ting Jiang, Yueyue Gao, Kebing Nie, Xianan Tang, Ying Chen, Dianxing Hu, Xudan Yang, Shixuan Wang, Meng Wu, Jinjin Zhang   +12 more
wiley   +1 more source

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

Tumor Lysis Syndrome Induced by Selpercatinib in Rearranged During Transfection (RET) Fusion-Positive Non-Small-Cell Lung Cancer. [PDF]

Cureus
Sagawa S, Tomoda Y, Shikama J, Awaya Y.
europepmc   +1 more source

Infection Masquerading As Spontaneous Tumor Lysis Syndrome. [PDF]

Cureus, 2023
DeSalvo J, Rossetti AL.
europepmc   +1 more source

Natural Killer Cells in Cancer Immunotherapy [PDF]

, 2019
Arndt MA, Chester C, Cortez VS, D'Andrea A, Elsasser D, Ferrini S, Gao Y, Hartmann F, Lotze MT, Miller JS, Orr MT, Seillet C, Soiffer RJ, Soto EO, Weiner LM, Yron I   +15 more
core   +1 more source

Gut Microbiota‐Derived Anandamide Mediates the Therapeutic Effects of Urolithin A on Alcohol‐Induced Cognitive and Social Dysfunction via CB1R‐DRD2‐RAP1 Signaling Axis

Advanced Science, EarlyView.
This study reveals that Urolithin A (UA) counteracts alcohol‐induced cognitive and social dysfunction (AICSD) via a gut microbiome‐dependent mechanism. UA‐enriched Bacteroids sartorii and Parabacteroids distasonis elevate anandamide (AEA), which activates the CB1R‐DRD2‐Rap1 signaling cascade to drive synaptic repair and reduce neuroinflammation ...
Hongbo Zhang, Zibin Li, Yao Xiao, Ji Bian, Caian He, Chao Liu, Lan Gong, Lin Han, Zhigang Liu, Min Wang   +9 more
wiley   +1 more source

Tumor Lysis Syndrome After mFOLFOX6 Administration for Ascending Colon Cancer. [PDF]

Cureus
Kano Y, Muranaka T, Saito W, Honma Y, Yokoyama D, Otsuka Y, Matsuda S, Takishin Y, Kunieda Y.   +8 more
europepmc   +1 more source

Cancer Cell‐Intrinsic Cholesterol Induces Lipid‐Associated Macrophage Differentiation via SP1 Palmitoylation to Promote Prostate Cancer Progression

Advanced Science, EarlyView.
Cancer cell‐intrinsic cholesterol promotes the S‐palmitoylation of SP1, increasing its nuclear translocation and driving the transcription and secretion of MDK, which in turn facilitates the differentiation of macrophages into a lipid‐associated phenotype.
Shirong Peng, Weilong Lin, Zean Li, Ruilin Zhuang, Shengmeng Peng, Bingheng Li, Bingliang Chen, Yong Luo, Yuan Ou, Wei Zhuang, Tao Du, Kaiwen Li, Hai Huang   +12 more
wiley   +1 more source

Continuous hemodiafiltration during chemotherapy for acute kidney injury in spontaneous tumor lysis syndrome due to high-grade B-cell lymphoma: a case report. [PDF]

CEN Case Rep
Kawamura N, Wada Y, Motohashi T, Okawa H, Kawamura S, Sakurabayashi S, Sano K, Takeuchi K, Naito S, Aoyama T, Takeuchi Y.   +10 more
europepmc   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source